[go: up one dir, main page]

WO2000060117A3 - Prediction des risques de pathologie interstitielle pulmonaire - Google Patents

Prediction des risques de pathologie interstitielle pulmonaire Download PDF

Info

Publication number
WO2000060117A3
WO2000060117A3 PCT/US2000/008492 US0008492W WO0060117A3 WO 2000060117 A3 WO2000060117 A3 WO 2000060117A3 US 0008492 W US0008492 W US 0008492W WO 0060117 A3 WO0060117 A3 WO 0060117A3
Authority
WO
WIPO (PCT)
Prior art keywords
interstitial lung
prediction
risk
lung disease
ild
Prior art date
Application number
PCT/US2000/008492
Other languages
English (en)
Other versions
WO2000060117A2 (fr
Inventor
Gordon W Duff
Giovine Francesco Saverio Di
Moria Whyte
Original Assignee
Interleukin Genetics Inc
Gordon W Duff
Giovine Francesco Saverio Di
Moria Whyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc, Gordon W Duff, Giovine Francesco Saverio Di, Moria Whyte filed Critical Interleukin Genetics Inc
Priority to IL14571400A priority Critical patent/IL145714A0/xx
Priority to JP2000609606A priority patent/JP2002540801A/ja
Priority to CA002367294A priority patent/CA2367294A1/fr
Priority to AU41837/00A priority patent/AU779701B2/en
Priority to EP00921536A priority patent/EP1192275A2/fr
Publication of WO2000060117A2 publication Critical patent/WO2000060117A2/fr
Publication of WO2000060117A3 publication Critical patent/WO2000060117A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes et des kits nouveaux permettant de déterminer si un sujet est atteint d'une pathologie interstitielle pulmonaire ou s'il est susceptible de développer une telle pathologie, telle que la fibrose pulmonaire. L'invention concerne également des méthodes de traitement d'une pathologie interstitielle pulmonaire et des essais de criblage pour identifier de nouvelles thérapeutiques contre ces pathologies.
PCT/US2000/008492 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire WO2000060117A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL14571400A IL145714A0 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease
JP2000609606A JP2002540801A (ja) 1999-04-02 2000-03-31 間質性肺疾患の危険性の予測
CA002367294A CA2367294A1 (fr) 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire
AU41837/00A AU779701B2 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease
EP00921536A EP1192275A2 (fr) 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28610899A 1999-04-02 1999-04-02
US09/286,108 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000060117A2 WO2000060117A2 (fr) 2000-10-12
WO2000060117A3 true WO2000060117A3 (fr) 2002-02-07

Family

ID=23097113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008492 WO2000060117A2 (fr) 1999-04-02 2000-03-31 Prediction des risques de pathologie interstitielle pulmonaire

Country Status (6)

Country Link
EP (1) EP1192275A2 (fr)
JP (1) JP2002540801A (fr)
AU (1) AU779701B2 (fr)
CA (1) CA2367294A1 (fr)
IL (1) IL145714A0 (fr)
WO (1) WO2000060117A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211566A1 (en) * 2000-10-10 2002-04-22 Grant W. Waterer Method for identifying increased risk of death from community acquired pneumonia
WO2003051388A2 (fr) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Nouvelle composition pharmaceutique d'interferon gamma ou de pirfenidone associe a des agents moleculaires diagnostiques permettant un traitement ameliore des affections pulmonaires interstitielles
US20030148288A1 (en) * 2002-02-01 2003-08-07 Yi-Wei Tang Colorimetric genetic test for clinically significant TNF polymorphism and methods of use thereof
EP1554400A1 (fr) * 2002-10-15 2005-07-20 Novartis AG Methodes pour prevoir des phenomenes d'oedeme comme effets secondaires de traitement medicamenteux
WO2006100446A2 (fr) * 2005-03-23 2006-09-28 Astrazeneca Uk Limited Procede
WO2006123943A1 (fr) 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methodes d'analyse de polymorphismes et leurs utilisations
EP4219760A3 (fr) * 2008-11-10 2023-09-06 Battelle Memorial Institute Procédés, compositions et dispositifs utilisant un microarn pour déterminer des états physiologiques
ES2660113T3 (es) * 2011-12-21 2018-03-20 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Procedimientos relacionados con la fibrosis pulmonar idiopática (FPI)
US9873920B2 (en) 2013-03-01 2018-01-23 Saitama Medical University Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting MUC4 gene polymorphism

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (fr) * 1992-04-30 1993-11-11 Synergen, Inc. Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
WO1997025445A1 (fr) * 1996-01-12 1997-07-17 Cedars-Sinai Medical Center Techniques de depistage de la rectocolite hemorragique par detection d'un polymorphisme d'un antagoniste du recepteur de l'interleukine-1
WO1998054359A1 (fr) * 1997-05-29 1998-12-03 Gordon Duff Prediction d'une maladie inflammatoire associee aux polymorphismes des loci sur le gene de l'il-1
WO1999024615A2 (fr) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (fr) * 1992-04-30 1993-11-11 Synergen, Inc. Methodes de traitement des maladies induites par l'interleukine-1 et le facteur de necrose tumorale
WO1997025445A1 (fr) * 1996-01-12 1997-07-17 Cedars-Sinai Medical Center Techniques de depistage de la rectocolite hemorragique par detection d'un polymorphisme d'un antagoniste du recepteur de l'interleukine-1
WO1998054359A1 (fr) * 1997-05-29 1998-12-03 Gordon Duff Prediction d'une maladie inflammatoire associee aux polymorphismes des loci sur le gene de l'il-1
WO1999024615A2 (fr) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCIS ET AL.: "Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease", CIRCULATION, vol. 99, February 1999 (1999-02-01), pages 861 - 866, XP001030756 *
HUANG SONG-LIH ET AL: "Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 156, no. 5, November 1997 (1997-11-01), pages 1436 - 1439, XP002180758, ISSN: 1073-449X *
MOFFATT MIRIAM F ET AL: "Tumour necrosis factor haplotypes and asthma.", HUMAN MOLECULAR GENETICS, vol. 6, no. 4, 1997, pages 551 - 554, XP002180759, ISSN: 0964-6906 *
WHYTE MOIRA ET AL: "Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 162, no. 2 Part 1, August 2000 (2000-08-01), pages 755 - 758, XP002180760, ISSN: 1073-449X *

Also Published As

Publication number Publication date
AU4183700A (en) 2000-10-23
CA2367294A1 (fr) 2000-10-12
EP1192275A2 (fr) 2002-04-03
IL145714A0 (en) 2002-07-25
JP2002540801A (ja) 2002-12-03
WO2000060117A2 (fr) 2000-10-12
AU779701B2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2000037679A3 (fr) Diagnostic et traitement d'une septicemie
WO1996012189A3 (fr) PROCEDES DE DEPISTAGE DE LA RECTOCOLITE HEMORRAGIQUE ET DE LA MALADIE DE CROHN PAR DETECTION DE L'AUTOANTICORPS VH3-15 ET DE pANCA
AU2002257162A1 (en) Humanized antibodies
WO2001055206A8 (fr) Acides nucleiques, proteines et anticorps
WO2000060117A3 (fr) Prediction des risques de pathologie interstitielle pulmonaire
HK1048632A1 (zh) 雜環取代的吡唑啉酮化合物
WO2000007025A3 (fr) Procedes relatifs a la prevision d'une reaction a des medicaments
GB9924957D0 (en) Novel treatment
DK0760010T3 (da) Fremgangsmåder til screening for Crohn's sygdom under anvendelse af TNF-mikrosatellit-alleler
PL2317324T3 (pl) Sposób identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2
EP1130401A3 (fr) Essais pour la mesure des fragments de collagène type II dans l'urine
WO2004020668A3 (fr) Methode de traitement du synovialome
WO2004107958A3 (fr) Marqueurs de sterol utilises en tant qu'outils de diagnostic dans la prevention des maladies atherosclereuses et en tant qu'outils d'aide a la selection d'agents a utiliser dans la prevention et le traitement de maladies atherosclereuses
WO2002077609A3 (fr) Identification de composes utiles dans le traitement ou la prevention des maladies proliferatives
WO2000043792A3 (fr) Procedes permettant de sequencer des polypeptides et kits a cet effet
WO2002004678A3 (fr) Diagnostic et traitement de la pré-éclampsie et des troubles trophoblastiques de la gestation et compositions à cet effet
AU2003242106A1 (en) Detection kit, assay plate to be used therein, detection method, evaluation method, polyclonal antibody of frog vitellogenin and procss for producing the same
WO2003019196A3 (fr) Diagnostic et traitement de l'atherosclerose
AU1309601A (en) Novel protein and dna thereof
WO2000078802A3 (fr) Polypeptides secretes et polynucleotides correspondants
ATE292800T1 (de) Immunologische bestimmung des hydrophoben lungensurfaktantproteins sp-c
WO2004111272A3 (fr) Polymorphisme du gene humain nbs1 servant au diagnostic d'une predisposition hereditaire au cancer
WO2002067766A8 (fr) Procedes et materiel d'evaluation des pathologies cardio-vasculaires
EP1097944A4 (fr) Anticorps specifique des domaines intracellulaires de la thyrosinephosphatase
GB0110036D0 (en) Methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367294

Country of ref document: CA

Ref country code: CA

Ref document number: 2367294

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609606

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921536

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000921536

Country of ref document: EP